2. Search Result
Search Result
Results for "

immune+thrombocytopenia

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

6

Inhibitory Antibodies

2

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-15306
    Eltrombopag
    Maximum Cited Publications
    24 Publications Verification

    SB-497115

    		 Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag
  • HY-15306A
    Eltrombopag Olamine
    Maximum Cited Publications
    24 Publications Verification

    Eltrombopag diethanolamine salt; SB-497115GR

    		 Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag Olamine
  • HY-147305
    Efgartigimod alfa

    ARGX-113

    		 Fc Receptor (FcR) Inflammation/Immunology
    Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research .
    Efgartigimod alfa
  • HY-P990706
    Povetacicept

    ALPN-303

    		 TNF Receptor Inflammation/Immunology
    Povetacicept (ALPN-303) is an engineered Fc fusion protein containing the TACI domain, and acts as a dual APRIL/BAFF antagonist. The Kd value of Povetacicept for human BAFF is 59.3 pM, while its Kd value for human APRIL is 1.00 pM. Povetacicept reduces the activation, proliferation, differentiation and survival of B cells, and inhibits the production of immunoglobulins and autoantibodies. Povetacicept can be used in research related to autoimmune hemolytic anemia, immune thrombocytopenia, systemic lupus erythematosus, lupus nephritis and myasthenia gravis .
    Povetacicept
  • HY-145598
    Sovleplenib

    HMPL-523

    		 Syk Cancer
    Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP) .
    Sovleplenib
  • HY-P990685
    Romiplostim

    		Cyclin G-associated Kinase (GAK) Cardiovascular Disease
    Romiplostim is an Fc-peptide fusion protein mimetic of TPO (thrombopoietin protein) and also a c-Mpl agonist. Romiplostim binds to c-Mpl, stimulates megakaryocyte-mediated thrombopoiesis, and activates the same downstream signaling pathways as endogenous TPO. Romiplostim is applicable to research related to hematopoietic acute radiation syndrome and chronic immune thrombocytopenia .
    Romiplostim
  • HY-122620
    Rafutrombopag (tautomerism)

    Hetrombopag (tautomerism); SHR-8735 (tautomerism)

    		 Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK Cardiovascular Disease Inflammation/Immunology
    Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
    Rafutrombopag (tautomerism)
  • HY-145589
    Rafutrombopag

    Hetrombopag; SHR-8735

    		 Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK Cardiovascular Disease Inflammation/Immunology Cancer
    Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
    Rafutrombopag
  • HY-170506
    KB-208

    		Thrombopoietin Receptor Inflammation/Immunology
    KB-208 is a phagocytosis inhibitor that acts similarly to intravenous immunoglobulin (IVIG). KB-208 improves immune thrombocytopenia (ITP) in a mouse model at a dose of 1 mg/kg. KB-208 does not affect other blood parameters and does not elevate serum biochemical markers of toxicity, and can be used in research in the field of immunity .
    KB-208
  • HY-15306S
    Eltrombopag-13C4
    1 Publications Verification

    SB-497115-13C4

    		 Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag- 13C4 (SB-497115- 13C4) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .
    Eltrombopag-13C4
  • HY-15306R
    Eltrombopag (Standard)

    SB-497115 (Standard)

    		 Reference Standards Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (Standard) is the analytical standard of Eltrombopag. This product is intended for research and analytical applications. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag (Standard)
  • HY-15306AR
    Eltrombopag Olamine (Standard)

    Eltrombopag diethanolamine salt (Standard); SB-497115GR (Standard)

    		 Reference Standards Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (Olamine) (Standard) is the analytical standard of Eltrombopag (Olamine). This product is intended for research and analytical applications. Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag Olamine (Standard)
  • HY-W713365
    Eltrombopag-d3

    SB-497115-d3

    		 Isotope-Labeled Compounds Thrombopoietin Receptor Apoptosis Bacterial Infection Cardiovascular Disease Cancer
    Eltrombopag-d3 (SB-497115-d3) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag-d3
  • HY-P991913
    CID-103

    TSK011010

    		 CD38 Cardiovascular Disease Inflammation/Immunology
    CID-103 (TSK011010) is an anti-CD38 antibody that recognizes a unique epitope on CD38. CID-103 can be used in research on immune thrombocytopenia .
    CID-103
  • HY-P991998
    Anti-Human/Monkey CD16a Antibody (3G8)

    		Fc Receptor (FcR) Inflammation/Immunology Cancer
    Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonal antibody targeting CD16a. Anti-Human/Monkey CD16a Antibody (3G8) blocks FcγRIII/CD16a, upregulates the metabolic activity of CD16+ cells, downregulates CD87, a poor prognostic marker, and inhibits the engraftment and growth of leukemia cells in acute myeloid leukemia, and rapidly increases platelet counts in immune thrombocytopenia. Anti-Human/Monkey CD16a Antibody (3G8) is applicable to research related to tumor immunology .
    Anti-Human/Monkey CD16a Antibody (3G8)

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: